Clinical trials: Liver Tumour
Chronic Liver Disease, Malignant Tumor
Intervention, Prognosis and Mechanism of Covid-19 Infection in Patients With Underlying Diseases
The goal of this observational study is to explore the influence of Covid-19 infection and risk factors of severe outcomes in vulnerable population including patients with chronic liver disease, malignant tumor, autoimmune…
- Conditions
- Chronic Liver Disease, Malignant Tumor, Autoimmune Diseases, Healthy
- Trial name
- NCT05965843
- Testing
- underling disease
- Volunteers
- 480 people
- Sponsor
- The Second Affiliated Hospital of Chongqing Medical University
Hepatocellular Carcinoma, Hepatic Metastasis
Palliative Radiotherapy (RT) for Liver Metastases (Mets) and Hepatocellular Carcinoma (HCC)(COLD 4)
Palliative radiotherapy is radiation treatment given to help reduce pain or discomfort, or other symptoms related to cancer. This is used commonly for cancer that has spread to the bones and brain, and for many other primary…
- Trial name
- NCT00923897
- Testing
- Palliative RT
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- University Health Network, Toronto
Cancer of Pancreas, Cancer of Liver
A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies
A Randomized, Double-Blind, Placebo-Controlled, Parallel, Multi-Center Study to Assess the Efficacy of BRCX014 Combined with Standard-Of-Care Treatment in Subjects with Glioblastoma Multiforme, Multiple Myeloma, and GI…
- Conditions
- Cancer of Pancreas, Cancer of Liver, Cancer of Rectum, Cancer of Colon
- Trial name
- NCT03607643
- Testing
- Cannabidiol, Bortezomib, Leucovorin
- Where
- United States
- Volunteers
- 160 people
- Sponsor
- Leaf Vertical Inc.
Hepatocellular Carcinoma
SHR-1210 Combined With Apatinib Mesylate in the Perioperative Therapy for Hepatocellular Carcinoma
The purpose of this study was to compare the efficacy and safety of camrelizumab + apatinib mesylate neoadjuvant therapy combined with camrelizumab adjuvant therapy and camrelizumab adjuvant therapy alone in patients with…
- Trial name
- CAPT (NCT04930315)
- Testing
- Apatinib Mesylate, Camrelizumab
- Where
- China
- Volunteers
- 78 people
- Sponsor
- Zhejiang University
Breast Carcinoma, Colon Carcinoma
Biospecimen Collection in Identifying Genetic Changes in Patients With Breast, Prostate, Colorectal, Liver, or Kidney Cancer or Multiple Myeloma Undergoing Surgery
This research trial studies how well biospecimen collection works in identifying genetic changes in patients with breast, prostate, colorectal, liver, or kidney cancer or multiple myeloma undergoing surgery.
- Conditions
- Breast Carcinoma, Colon Carcinoma, Invasive Carcinoma, Kidney Carcinoma
- Trial name
- NCT04955808
- Testing
- Biospecimen Collection, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 2,400 people
- Sponsor
- National Cancer Institute (NCI)
Liver Cancer
Chemotherapy in Treating Patients With Liver Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving drugs in different ways may kill more tumor cells.
- Trial name
- NCT00003044
- Testing
- cisplatin-e therapeutic implant
- Where
- 3 sites in United States, Hong Kong
- Volunteers
- 55 people
- Sponsor
- Matrix Pharmaceutical
NAFLD, NASH
The European NAFLD Registry
The European NAFLD Registry is a prospectively recruited, observational study supporting the study of the clinical phenotype, natural history, disease outcomes and pathophysiology of Non-Alcoholic Fatty Liver Disease and…
- Conditions
- NAFLD, NASH, NASH - Nonalcoholic Steatohepatitis, Fibrosis, Liver
- Trial name
- NCT04442334
- Where
- 37 sites in Belgium, Finland and 10 more
- Volunteers
- 10,000 people
- Sponsor
- Newcastle University
Hepatocellular Carcinoma
Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC)
Open-label study to evaluate the safety and tolerability of Sorafenib dose ramp-up (starting at a lower dose and then gradually increasing the dose) versus standard Sorafenib dosing in subjects with unresectable and/or metastatic…
- Trial name
- NCT01203787
- Testing
- Sorafenib Standard Dosing Regimen, Sorafenib Ramp-Up Regimen
- Where
- 9 sites in United States
- Volunteers
- 120 people
- Sponsor
- University of Florida
Cirrhosis, Hepatocellular Carcinoma
Study of High-Dose Oral Vitamin D for the Prevention of Liver Cancer
The purpose of this study is to evaluate the safety and tolerability of a high dose of vitamin D (VD) in patients with cirrhosis.
- Trial name
- NCT01956864
- Testing
- Vitamin D
- Where
- United States
- Sponsor
- Johns Hopkins University
Neuroendocrine Tumors
Selective Intra-arterial Injection of PRRT in Neuroendocrine Tumor Patients With Liver Metastases
This is a safety study to determine the phase 1 starting dose of [90]Yttrium-DOTATOC when it is administered intravenously for patients with neuroendocrine tumors that have spread to the liver.
- Trial name
- NCT03724409
- Testing
- [90]Y-DOTATOC
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Sandeep Laroia
Hepatocellular Carcinoma
Autologous HBV-specific T Cell Receptor Engineered T Cells (TCR-T) in Patients With HBV-related Advanced HCC
Adoptive cell therapy with TCR-T cells targeting HBV antigens represents an innovative opportunity for treatment of HBV-related HCC.
- Trial name
- NCT05339321
- Testing
- SCG101, PD1/PD-L1 checkpoint inhibitor
- Where
- 4 sites in China
- Volunteers
- 36 people
- Sponsor
- Peking Union Medical College Hospital
Hepatocellular Carcinoma
Personalized Cancer Vaccine in Egyptian Cancer Patients
Evaluate safety and immunogenicity of peptide cancer vaccine in patients with hepatocellular carcinoma (HCC) who developed recurrence after surgical resection and refractory to the available institutional standard of care lines…
- Trial name
- PROVE (NCT05059821)
- Testing
- Peptide cancer vaccine
- Where
- Egypt
- Volunteers
- 10 people
- Sponsor
- zeinab ahmed yousif hasan ashour
Hepatocellular Carcinoma
SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)
A Phase 2 open-label, single-arm, non-randomized study in the treatment of advanced hepatocellular carcinoma (HCC) patients who failed prior treatment with sorafenib using a Simon's 2-stage design.
- Trial name
- NCT01752933
- Testing
- SGI-110
- Where
- 24 sites in United States, Canada and 1 more
- Volunteers
- 52 people
- Sponsor
- Astex Pharmaceuticals, Inc.
Hepatocellular Carcinoma
Trial Comparing PLA to HIGRT (PROVE-HCC)
This phase II, randomized trial compare Quality of Life for patients with Hepatocellular Carcinoma (HCC) who are not surgical candidates or decline surgery and are treated with Percutaneous Local Ablation (PLA) or…
- Trial name
- PROVE-HCC (NCT03402607)
- Testing
- Percutaneous Local Ablation, Hypofractionated Image Guided Radiation Therapy
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Duke University
Hepatocellular Carcinoma(HCC)
Individualized Comprehensive Treatment for Advanced Hepatocellular Carcinoma
This project is a prospective, multi-center, multi-cohort exploratory clinical study. It focuses on patients with advanced hepatocellular carcinoma who experience disease progression after first-line standard therapy.
- Trial name
- ICT-HCC (NCT06893887)
- Testing
- FOLFOX4, Adebrelimab, Apatinib
- Where
- China
- Volunteers
- 270 people
- Sponsor
- Nanjing Tianyinshan Hospital
Hepatocellular Carcinoma
To Evaluate the Safety and Efficacy of Microwave Ablation Therapy in Patients With Primary Liver Cancer
Through the implementation of prospective, multi-center, single-group target value research to verify the safety and effectiveness of the microwave ablation treatment system for the ablation treatment of primary liver cancer.
- Trial name
- NCT04520906
- Testing
- microwave ablation
- Where
- 13 sites in China
- Volunteers
- 61 people
- Sponsor
- Suzhou Hengruihongyuan Medical Technology Co. LTD
HCC, Hepatocellular Carcinoma
CEUS vs. AMRI for HCC Detection in Patients With Indeterminate Liver Nodules
The study will be conducted at the following locations: 1. UT Southwestern Medical Center 2. Parkland Health and Hospital System 3.
- Trial name
- NCT06184152
- Testing
- CEUS imaging, aMRI imaging
- Where
- 2 sites in United States
- Volunteers
- 600 people
- Sponsor
- University of Texas Southwestern Medical Center
HCC - Hepatocellular Carcinoma, Hepatic Arterial Infusion Chemotherapy
HAIC in Combination With PD-1 Inhibitors and Lenvatinib for High Tumor Burden Advanced HCC (CHANCE2416)
The purpose of this study is to evaluate the safety and efficacy of hepatic arterial infusion chemotherapy (HAIC) in combination with PD-1 inhibitors and Lenvatinib in patients with high tumor burden advanced-stage hepatocellular…
- Conditions
- HCC - Hepatocellular Carcinoma, Hepatic Arterial Infusion Chemotherapy, BCLC Stage C Hepatocellular Carcinoma, Lenvatinib
- Trial name
- NCT06631326
- Testing
- hepatic artery infusion chemotherapy, Lenvatinib + PD-1 monoclonal antibody
- Where
- China
- Volunteers
- 244 people
- Sponsor
- First Hospital of China Medical University
Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma
Sulfur Colloid SPECT/CT in Measuring Liver Function in Patients With Primary or Metastatic Liver Cancer Undergoing Radiation Therapy or Surgery
This pilot trial studies how well single photon emission computed tomography (SPECT)/computed tomography (CT) with technetium Tc-99m sulfur colloid works in measuring liver function in patients with liver cancer that has or has…
- Conditions
- Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma, Stage IV Liver Cancer, Stage IVA Liver Cancer
- Trial name
- NCT02881554
- Testing
- Computed Tomography, Single Photon Emission Computed Tomography, Technetium Tc-99m Sulfur Colloid
- Where
- 2 sites in United States
- Volunteers
- 41 people
- Sponsor
- University of Washington
Adult Hepatocellular Carcinoma, Advanced Adult Hepatocellular Carcinoma
MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy
This phase II trial is studying how well MK2206 works in treating patients with advanced liver cancer that did not respond to previous therapy.
- Conditions
- Adult Hepatocellular Carcinoma, Advanced Adult Hepatocellular Carcinoma, Localized Non-Resectable Adult Liver Carcinoma, Recurrent Adult Liver Carcinoma
- Trial name
- NCT01239355
- Testing
- Akt Inhibitor MK2206, Laboratory Biomarker Analysis
- Where
- 22 sites in United States
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.